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Abstract
Background: Platelet-derived growth factor receptor α (PDGFRα) expression is increased in activated hepatic stellate
cells (HSCs) in cirrhotic liver, while normal hepatocytes express PDGFRα at a negligible level. However, cancerous
hepatocytes may show upregulation of PDGFRα, and hepatocellular carcinoma is preceded by chronic liver injury.
The role of PDGFRα in non-cancerous hepatocytes and liver fibrosis is unclear. We hypothesized that upon liver
injury, PDGFRα in insulted hepatocytes contributes to liver fibrosis by facilitating intercellular crosstalk between
hepatocytes and HSCs.
Methods: Hepatocytes were isolated from normal and thioacetamide (TAA)-induced cirrhotic livers for assessment
of PDGFRα expression. Conditional knock-out (KO) C57BL/6 mice, in which PDGFRα was selectively deleted in
hepatocytes, were generated. Liver fibrosis was induced by injecting TAA for 8 weeks. Hep3B cells were transfected
with a small interfering RNA (siRNA) (PDGFRα or control) and co-cultured with LX2 cells.
Results: PDGFRα expression was increased in hepatocytes from fibrotic livers compared to normal livers.
Conditional PDGFRα KO mice had attenuated TAA-induced liver fibrosis with decreased HSC activation and
proliferation. Immunoblot analyses revealed decreased expression of phospho-p44/42 MAPK in TAA-treated KO
mice; these mice also showed almost complete suppression of the upregulation of mouse double minute 2.
Although KO mice exhibited increased expression of transforming growth factor (TGF)-β and Smad2/3, this was
compensated for by increased expression of inhibitory Smad7. LX2 cells co-cultured with PDGFRα siRNA-infected
Hep3B cells showed decreased PDGFRα, α smooth muscle actin, collagen α1(I), TGFβ, and Smad2/3 expression. LX2/
PDGFRα-deleted hepatocyte co-culture medium showed decreased PDGF-BB and PDGF-CC levels.
Conclusions: Deletion of PDGFRα in hepatocytes attenuated the upregulation of PDGFRα in HSCs after TAA
treatment, resulting in decreased liver fibrosis and HSC activation. This suggests that in the event of chronic liver
injury, PDGFRα in hepatocytes plays an important role in liver fibrosis by affecting PDGFRα expression in HSCs.
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Background
Liver fibrosis is a multicellular response to liver injury in
which hepatic stellate cells (HSCs) are responsible for 90%
of extracellular matrix (ECM) production [1–5]. Liver fi-
brosis upon acute liver injury may be beneficial by provid-
ing mechanical stability and facilitating the restoration of
hepatic architecture and function. However, repetitive
chronic liver insults result in liver fibrosis, which may pro-
gress to cirrhosis [3, 6, 7], the major contributing factor to
development of hepatocellular carcinoma (HCC) [8].
Upon liver injury, HSCs are activated by cytokines,
including platelet-derived growth factors (PDGFs),
which are potent mitogens [9, 10]. PDGFs exist as five
isoforms: PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC,
and PDGF-DD. The cellular effects of PDGFs require
the function of cell surface receptor tyrosine kinases
comprising platelet-derived growth factor receptor
(PDGFR)α and PDGFRβ subunits [11, 12]. Elevated
PDGFR expression is observed in human cardiac fibro-
sis after myocardial infarct, pulmonary fibrosis, kidney
fibrosis, and liver fibrosis [13–16].
PDGFR expression is very low in the normal adult liver
but is significantly upregulated in HSCs in cirrhotic liver
[17]. PDGFRα participates in liver fibrosis, as evidenced
by increased PDGFRα expression in cirrhotic human
livers, human cell lines, and a mouse model of liver fibro-
sis [18, 19]. Stimulation of PDGFRα expression in HSCs
induces their activation and proliferation [16, 20–23], and
blocking of PDGFRα expression suppresses HSC prolifera-
tion [24]. In addition, stimulation of PDGFRα expression
by excessive production of PDGF-CC induces liver cirrho-
sis and HCC in PDGF-C transgenic (Tg) mice [25, 26].
PDGFRα expression in the liver is markedly increased in
PDGF-C Tg mice, although the responsible cell type is
unclear.
Normal adult hepatocytes show negligible PDGFRα
expression. However, hepatocytes in embryos may have
enhanced PDGFRα expression, which later is markedly
attenuated [27]. Therefore, the role of PDGFRα expres-
sion in adult hepatocytes in liver fibrosis is unknown.
However, the increased PDGFRα expression in HCC sub-
sets in the absence of background liver cirrhosis suggests
that abnormal hepatocytes overexpress PDGFRα [28].
Our preliminary study demonstrated that PDGFRα ex-
pression was increased in not only stimulated HSCs but
also injured hepatocytes. We hypothesized that PDGFRα
in hepatocytes in the setting of chronic liver injury plays
an important role in liver fibrosis by facilitating intercel-
lular crosstalk between hepatocytes and HSCs.
We report for the first time that conditional abolition of
PDGFRα expression in hepatocytes attenuates chemically
induced liver fibrosis by suppressing the upregulation of
PDGFRα and TGFβ in HSCs, reducing their activation
and proliferation.
Methods
Generation of PDGFRα conditional KO mice
Homozygous PDGFRαloxp/Loxp mice with targeted deletion
of exons 1 to 4 and albumin (alb)-Cre mice, both on
the C57BL/6 background, were obtained from Jackson
Laboratories (Bar Harbor, ME). PDGFRαloxp/Loxp mice
were crossbred with Alb-Cre mice to obtain offspring
carrying PDGFRαloxp/wt;Alb-Cre. Next, PDGFRαloxp/wt;Alb-
Cre were bred to PDGFRαloxp/Loxp mice, resulting in
PDGFRαloxp/Loxp;Alb-Cre+/− or KO mice. Mice of all other
genotypes, including PDGFRαloxp/Loxp;Alb-Cre−/− and
PDGFRαloxp/wt;Alb-Cre−/−, are referred to as wild-type
(WT) controls.
Animals and thioactetamide-induced liver fibrosis
All experiments on mice were approved by the Institu-
tional Animal Use and Care Committee (IACUC) at
Gangnam Severance Hospital, Yonsei University College
of Medicine (permit number 0031) in accordance with the
recommendations and restrictions of the IACUC, which
follows the guidelines of the United States National Insti-
tutes of Health.
Male 8-week old C57BL/6 (WT) and PDGFRα condi-
tional KO mice (PDGFRα KO) were used. The animals
were housed with a 12 h light:dark cycle and fed standard
chow. For the fibrosis groups, thioacetamide (TAA) (300
mg/kg body weight) was injected intraperitoneally into
male WT and PDGFRα KO mice during the light cycle
twice weekly for 8 weeks. One week after the final TAA
treatment, the mice were fasted for 14–16 h with free ac-
cess to water and subsequently euthanized. Untreated
age-matched WT or PDGFRα KO male mice were eutha-
nized after the fast.
The animal experiment groups were as follows: WT-
control (n = 5), untreated WT mice; KO-control (n = 5),
untreated PDGFRα conditional KO mice; WT-TAA (n = 5),
WT mice treated with TAA for 8 weeks; and KO-TAA
(n = 5), PDGFRα conditional KO mice treated with TAA
for 8 weeks.
Hepatocyte and HSC isolation
Hepatocytes and HSCs were isolated from WT and
WT-TAA mice by an in situ collagenase perfusion
method as described previously with modifications [29].
Protein and RNA were extracted from the isolated hepa-
tocytes for analyses.
HCC tissue
Freshly frozen liver-tissue specimens from livers
resected due to HCC or metastatic liver cancer were
used. The liver specimens were archived at the Tissue
Bank of Yonsei University College of Medicine, Gangnam
Severance Hospital with the patients’ consent. The
non-tumor sites of liver specimens with hepatitis but not
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liver cirrhosis as determined via pathologic evaluation
(n = 7) were compared to liver specimens from meta-
static liver cancer patients (n = 7) that appeared normal
on pathologic assessment. This study was approved by
the Institutional Review Board of Gangnam Severance
Hospital, Yonsei University College of Medicine, Seoul,
Republic of Korea (3–2015–0045).
Immunohistochemical analyses and terminal dUTP nick
end-labeling assay
Liver-tissue specimens were stained with Masson’s tri-
chrome and the fibrosis ratio was calculated using an
image analysis system as described previously with modifi-
cations [30]. The total area was calculated as the sum of
the area of the microscopic fields, including parenchyma
and fibrosis. For each slide, the area of fibrosis was evalu-
ated in 20 consecutive fields at a magnification of × 200,
and averaged.
Sections of mouse liver tissue specimens were immuno-
stained using a mouse anti-human alpha-smooth muscle
actin (αSMA) primary antibody (DAKO, Carpinteria, CA).
Detection of the primary antibody was carried out by the
immunoperoxidase technique using an ABC Kit (Vector
Laboratories) as a measure of HSC activation. Peroxidase
activity was determined by reaction with diaminobenzi-
dine tetrahydrochloride (DAB). Data are total numbers
of αSMA-positive cells present in 10 high-power fields
(× 400) per sample.
Apoptosis was evaluated by terminal dUTP nick
end-labeling (TUNEL) assay. The TUNEL assay detects
fragmentation of nuclear DNA during apoptotic cell death
in situ, and was performed using an ApopTag Peroxidate
In Situ Apoptosis Detection Kit (Millipore, USA). For each
slide, the area of immunostained apoptotic nuclei by
3’-OH-end labeling of fragmented DNA was evaluated
in 20 consecutive fields at a magnification of × 200,
and averaged.
Sections of human liver-tissue specimens were immu-
nostained with a mouse anti-PDGFRα antibody (Santa
Cruz Biotechnology, Santa Cruz, CA) and assessed at a
magnification of × 400.
siRNA transfection
Transient knockdown assays were performed using Dharr-
maFECT 1 (Dharmacon, Lafayette, CO), according to the
manufacturer’s instructions. PDGFRα (#5156) and control
(D-001206-13) siRNAs were purchased from Dharmacon.
Cell lines and in vitro experiments
Hep3B (KCLB #88064) and LX2 (cat #SCC064) cells
were purchased from the Korean Cell Line Bank (Seoul,
Republic of Korea), and EMD Millipore (Temecula,
CA), respectively, and maintained as described previ-
ously [31, 32].
Cells were cultured using hanging cell-culture inserts
(1 μm pore size, Falcon) to separate cell populations. Wells
and inserts with medium were allowed to stabilize for 24 h
at 37 °C according to the manufacturer’s recommenda-
tions. Hep3B cells were seeded in the insert (3 × 103 cells/
cm2) and allowed to attach overnight in Dulbecco’s modi-
fied Eagle’s medium (DMEM) with 10% fetal bovine serum
(FBS). The following day, siRNA (PDGFRα or control)
was transfected into Hep3B cells using DharmaFECT 1
(Dharmacon, Lafayette, CO), according to the manufac-
turer’s instructions. Briefly, LX2 cells (3 × 105/cm2) were
seeded on a six-well plate and incubated for 24 h. Hep3B
cells were plated separately on a culture insert and trans-
fected with the PDGFRα or control siRNA. After a 6 h sta-
bilizing period, the insert containing treated Hep3B cells
was placed above the plate with LX cells and incubated
for a further 24 h. LX2 Cells and supernatants were har-
vested and recovered for further analyses.
Cell viability assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay was used to evaluate the prolifera-
tion of LX cells. Following co-culture for 24 h, 5 mg/mL
MTT was added to the culture medium (Sigma-Aldrich,
St. Louis, MO) and incubated for 4 h at 37 °C. The
supernatant was removed, the cells were treated with
150 μL/well dimethyl sulfoxide, and the absorption at
470 nm was measured. The assay was carried out in trip-
licate and each experiment was repeated at least three
times. Data are percentages of surviving cells relative to
the control.
RNA isolation and real-time polymerase chain reaction
Total RNA was extracted from frozen whole livers or
isolated cells using TRIzol reagent (Invitrogen, Carlsbad,
CA) or Qiagen mini columns (Qiagen Inc. Valencia, CA)
according to the manufacturer’s protocol. RNA concen-
trations were quantified by spectrophotometry. RNA
integrity was assessed by agarose gel electrophoresis
and ethidium bromide staining. The RNA samples were
diluted in RNase-free water and stored at − 70 °C until
use. Five micrograms of RNA were reverse-transcribed
using the RNA PCR Kit, version 1.2 (TaKaRa Bio Inc.,
Japan) according to the manufacturer’s recommenda-
tions. Oligonucleotide primers and a TaqMan probe for
PDGFRα; TGF-β; Smad 2, 3, and 7; collagen α1(I)
(Col1α(I)); αSMA; bax; bcl-2; and MDM2 were used,
with 18S as the internal control. The probes were
obtained from Applied Biosystems (Perkin-Elmer/PE
Applied Biosystems, Foster City, CA). The TaqMan
probe was labeled at the 5′-end with the reporter dye
FAM and at the 3′-end with a minor groove binder
(MGB) nonfluorescent quencher. Quantitative polymer-
ase chain reaction (qPCR) was performed in triplicate
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for each sample on a Step One Plus Real Time System
(Applied Biosystems). Each 20 μL reaction contained
10 μL TaqMan Fast Universal Master Mix (Applied Bio-
systems, Darmstadt, Germany), 1 μL Gene Expression
Mix, and 2 μL cDNA diluted in 7 μL RNase-free water.
The thermal cycler conditions were 20 s at 95 °C,
followed by 40 cycles of 5 s at 95 °C and 20 s at 60 °C.
Fold changes in the expression of target genes relative
to the endogenous 18S control were calculated as de-
scribed previously [33].
Protein extraction and immunoblotting
Whole-liver lysates were prepared in Triton-X 100 lysis
buffer containing protease inhibitors and protein con-
centrations were quantified using the Bradford method
with bovine serum albumin (BSA) as the standard.
Resolution by SDS-PAGE was followed by immunoblot-
ting using the following antibodies: rabbit anti-PDGFRα
(#3164), rabbit anti-phospho-p44/42 MAPK (#9101),
rabbit anti-p44/42 MAPK (#9102), rabbit anti-β actin
(#4(a967), all from Cell Signaling (Danvers, MA) and
anti-phospho-Smad3 (#ab52903) from Abcam (Cambridge,
MA). Epitope-primary antibody complexes were detected
using species-specific secondary antibodies conjugated to
horseradish peroxidase (HRP) followed by enhanced chemi-
luminescence (ECL) (Thermo Fisher Scientific Pierce, IL).
Determination of PDGF-CC and -BB levels in culture
medium
The levels of PDGF-CC and PDGF-BB in culture medium
were quantified using a Quantikine enzyme-linked im-
munosorbent assay (ELISA) Kit (R&D Systems, Minneap-
olis, MN) according to the manufacturer’s instructions.
Statistical analyses
Results are shown as means ± standard errors of the mean
(SEMs). Data were subjected to nonparametric analyses
(Kruskal–Wallis or Mann–Whitney test) or one-way ana-
lysis of variance (ANOVA) with Tukey’s post hoc test. A
value of P < 0.05 was considered indicative of statistical
significance. All calculations were performed in IBM SPSS
Statistics version 23 for Windows.
Results
PDGFRα deletion in hepatocytes attenuated the TAA-
induced increase in PDGFRα expression in the whole liver
The level of PDGFRα expression is increased in fibrotic
liver due to its overexpression in HSCs [19, 34]. Non-
insulted hepatocytes scarcely express PDGFRα [19].
Hepatocytes from TAA-treated livers showed in-
creased PDGFRα expression compared to those from
normal livers (Fig. 1a). To address the role of hepatocyte
PDGFRα in liver fibrosis, we generated hepatocyte-specific
Fig. 1 Attenuation of PDGFRα expression in TAA-treated livers after conditional deletion of PDGFRα in hepatocytes. a PDGFRα in hepatocytes.
b Identification of hepatocyte PDGFRα-deleted knockout (KO) mice by genotyping PCR (lane 2). c PDGFRα expression in the liver of wild-type
(WT) and hepatocyte PDGFRα-deleted KO mice (d) Western blotting analyses; densitometry values normalized to that of β-actin are shown.
*P < 0.05, compared to that of TAA-untreated WT mice. **P < 0.05, compared to WT mice under identical conditions
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conditional PDGFRα KO mice (Fig. 1b). The non-insulted
livers (control) of WT and conditional KO mice showed no
significant differences in PDGFRα expression (Fig. 1c).
However, the livers of TAA-treated WT mice, but not those
of TAA-treated KO mice, had enhanced PDGFRα expres-
sion (Fig. 1c).
Immunoblot analyses of the whole liver showed an
increased PDGFRα protein level in TAA-treated WT
mice, and a significantly reduced PDGFRα protein level
in TAA-treated KO mice (Fig. 1d).
PDGFRα deletion in hepatocytes alleviated TAA-induced
HSC activation and liver fibrosis
The fibrotic area in the liver was increased by TAA in
both WT and KO mice (Fig. 2a). However, PDGFRα
conditional KO mice showed significantly attenuated liver
fibrosis compared to WT mice (Fig. 2a). Quantitative
analyses of col1α(I) expression yielded a result comparable
with the histologic findings (Fig. 2b).
The TAA-induced increase in the expression of αSMA,
a marker of HSC activation, was significantly abolished by
deletion of PDGFRα (Fig. 2c). The number of
αSMA-positive cells was significantly increased and de-
creased by TAA in the liver of WT and KO mice, respect-
ively (Fig. 2d).
Deletion of PDGFRα in hepatocytes attenuates ERK
activation
ERK is a downstream signaling factor involved in PDGF-
induced activation of PDGFR [35]. Immunoblot analyses
of phospho-p44/42 MAPK (ERK1/2) revealed increased
phosphorylation of ERK1/2 in the livers of WT and KO
TAA-treated mice compared to the controls. However,
Fig. 2 Suppression of TAA-induced liver fibrosis by hepatocyte platelet-derived growth factor receptor (PDGFR) α deletion. a Area of fibrosis.
b Expression of (b) Col1α(I) and c αSMA. d Number of αSMA-positive cells. e Western blotting analyses; densitometry values are shown. *P < 0.05,
compared to TAA-untreated WT mice. **P < 0.05, compared to WT mice under identical conditions
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KO mice showed significantly attenuated phosphorylation
of ERK1/2 compared to WT TAA-treated mice (Fig. 2e).
Deletion of PDGFRα did not influence hepatocyte
apoptosis
TAA treatment increased the number of cells displaying
nuclear fragmentation compared to the control. Deletion
of PDGFRα in hepatocytes did not affect apoptosis irre-
spective of TAA treatment, similar to the WT control
(Fig. 3a, b). Bcl-2 inhibits apoptosis whereas Bax promotes
it [36], and the Bcl-2/Bax ratio is a marker of survival after
apoptotic stimuli [37]. The liver Bcl-2/Bax ratio did not
differ significantly between WT and KO mice after TAA
treatment (Fig. 3c).
Effect of hepatocyte PDGFRα deletion on TGFβ signaling
Activation of PDGFR by excessive PDGF ligands results
in upregulation of the TGFβ/Smad signaling pathway to
facilitate HSC proliferation and collagen production [38].
In this study, deletion of PDGFRα in hepatocytes resulted
in increased TGFβ expression in normal and TAA-treated
livers compared to the WT (Fig. 4a). Downstream signal-
ing of TGFβ and Smad2/3 was also upregulated by dele-
tion of PDGFRα in hepatocytes in both normal and
TAA-induced fibrotic livers compared to the WT (Fig. 4b,
c). The protein level of Smad3 showed a similar trend to
the mRNA level (Fig. 4d). Smad7 was significantly upregu-
lated in the liver of conditional PDGFRα-deleted mice; this
likely compensated for the effects of enhanced TGF-β sig-
naling (Fig. 4d).
Deletion of PDGFRα in hepatocytes blocked upregulation
of MDM2
MDM2 is a negative regulator of p53 and is considered an
oncogene [39, 40]. Activation of PDGRα independently of
PDGF results in activation of MDM2 and suppression of
p53 [41, 42]. TAA-induced liver injury was accompanied
by upregulation of MDM2 in the liver; this was blocked by
deletion of PDGFRα in hepatocytes (Fig. 5a).
To speculate on the cellular components responsible
for the TAA-induced increase in MDM2 expression, he-
patocytes and HSCs were isolated from TAA-treated
livers and MDM2 expression was evaluated. Although
both hepatocytes and HSCs from injured livers showed
increased MDM2 expression, the magnitude of the up-
regulation was significantly greater in hepatocytes than
in HSCs (Fig. 5b).
Co-culture with PDGFRα-deleted Hep3B cells decreased
PDGFRα expression in, and suppressed the activation of,
LX2 cells
Hep3B cells have elevated PDGFRα expression [19, 43].
Culture of LX2 cells with PDGFRα-silenced Hep3B cells
attenuated PDGFRα expression in the former (Fig. 6a).
They had decreased αSMA and col1α(I) expression com-
pared to that on LX2 cells, co-cultured with Hep3B cells
with normally expression PDGFRα (Fig. 6b, c).
LX2 cells were co-cultured with PDGFRα-silenced or
control Hep3B cells for 24 h. The proliferation of LX2
cells was reduced by co-culture with PDGFRα-silenced
Hep3B cells (Fig. 6d).
Fig. 3 Effects of conditional PDGFRα deletion on hepatocyte morphology and apoptosis. a Hematoxylin and eosin (HE) staining (× 400), Masson’s
trichrome staining (× 200), and TUNEL staining (× 400) of the liver. b Area of immunostained liver. c Liver Bcl-2: Bax expression ratios. *P < 0.05,
compared to TAA-untreated WT mice. **P < 0.05, compared to WT mice under identical conditions
Lim et al. Cell Communication and Signaling           (2018) 16:93 Page 6 of 11
TGF β signaling in LX2 cells co-cultured with PDGFRα-
silenced Hep3B cells
LX2 cells cultured with PDGFRα-silenced Hep3B cells
exhibited attenuated expression of TGFβ, and Smad2/3
(Fig. 6e). However, expression of Smad7 was not down-
regulated by co-culture with PDGFRα-silenced Hep3B
cells (Fig. 6e).
PDGF ligands in PDGFRα-silenced Hep3B cell co-culture
medium
The levels of PDGF-BB and PDGF-CC were significantly
reduced in the co-culture medium of LX2 cells with
PDGFRα-silenced Hep3B cells, and the reduction in the
PDGF-BB level was of greater magnitude than that in
the PDGF-CC level (Fig. 7).
PDGFRα expression in human liver with hepatitis without
advanced fibrosis
Expression of PDGFRα was examined in normal human
liver and human liver with hepatitis but not advanced
fibrosis. Immunohistochemistry showed expression of
PDGFRα at the hepatocyte membrane and in nonpar-
enchymal cells in the liver with hepatitis, whereas the
normal liver exhibited no PDGFRα staining (Fig. 8a).
Whole-cell lysates from livers with pathologically
proven hepatitis but not advanced fibrosis (n = 7) were
examined for col1α(I) and PDGFRα expression and
compared to that in normal liver tissue (n = 7). Livers
with hepatitis but not significant liver fibrosis showed
elevated PDGFRα expression compared to the normal
livers, but col1α(I) expression was not significantly dif-
ferent (Fig. 8b).
Fig. 4 Effect of hepatocyte PDGFRα deletion on TGF-β signaling in TAA-treated mouse liver. Expression of (a) TGFβ (b), Smad2 (c), and Smad3.
d Western blotting analyses of Smads; densitometry values normalized to that of β-actin are shown. e Expression of inhibitory Smad7. *P < 0.05,
compared to TAA-untreated WT mice. **P < 0.05, compared to WT mice under identical conditions
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Discussion
PDGFRα expression is markedly elevated in chronic liver
injury and enhanced PDGFRα activation contributes to
liver fibrosis [19, 34]. The proliferation of PDGFRα-posi-
tive HSCs during liver fibrosis can be suppressed by block-
ing of PDGFRα in HSCs [24]. While only PDGFRα in
HSCs has been thought to play a role in liver fibrosis, we
report that PDGFRα is upregulated in injured hepatocytes,
which contributes to HSC proliferation, resulting in liver
fibrosis. Deletion of PDGFRα in hepatocytes significantly
attenuated TAA-induced liver fibrosis. PDGFRα in he-
patocytes plays an important role in liver fibrosis by indu-
cing HSC activation and proliferation; in vitro, HSCs
co-cultured with PDGFRα-deleted hepatocytes exhibited
attenuated activation and decreased collagen production.
Normal adult hepatocytes express a low level of
PDGFRα, the role of which in hepatocytes in liver fibrosis
was unclear. However, PDGFRα is reportedly expressed in
cancerous hepatocytes, and facilitates the proliferation
and migration of HCC cells, which are related to invasion
Fig. 5 Effect of hepatocyte PDGFRα deletion on MDM2 upregulation after TAA-induced liver injury. a MDM2 expression in the liver normalized
to that of the 18S rRNA gene. *P < 0.05, compared to TAA-untreated WT mice. **P < 0.05, compared to WT mice under identical conditions.
b Expression of MDM2 in hepatocytes and HSCs. *P < 0.05, compared to normal liver cells
Fig. 6 Changes in LX2 cells co-cultured with Hep3B cells with or without PDGFRα deletion. a Expression of (a) PDGFRα, b col1α(I) and c αSMA in
LX2 cells co-cultured with Hep3B cells with or without PDGFRα silencing. d MTT assay results. e Expression of TGFβ, Smad2, Smad3, and Smad7 in
LX2 cells. *P < 0.05, compared to LX2 cells co-cultured with PDGFRα-preserved Hep3B cells
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and metastasis [44, 45]. Hepatocytes expressing dominant-
negative PDGFRα revealed decreased TGF-β-induced mi-
gration and tumor formation [44]. Therefore, our data sug-
gest that PDGFRα in injured hepatocytes also contributes
to liver fibrosis, the most important risk factor for HCC.
siRNA KO of PDGFRα in hepatocytes resulted in de-
creased PDGF-BB and PDGF-CC levels in co-culture
medium compared to co-culture of non-KO hepato-
cytes. Because activated HSCs are possible sources of
PDGF ligands [46], and HSC activation was attenuated by
PDGFRα deletion in hepatocytes, the reduced PDGF-BB
and PDGF-CC levels were likely due to decreased produc-
tion by HSCs. In addition, the decrement in the PDGF-BB
level was of greater magnitude than that in the PDGF-CC
level. PDGF-BB is reportedly the most potent mitogen for
HSC activation, and some animal models of fibrosis, such
as the bile-duct ligation model, show upregulation of
PDGF-BB and PDGF-CC, but the latter to a lesser extent
[47]. The mechanism by which PDGFRs on hepatocytes
are activated is unclear. Increased ERK activation was
detected in the livers of TAA-treated WT and KO mice,
suggesting that PDGF ligands mediate PDGFR activa-
tion upon liver insult; the PDGFRα KO mice exhibited
attenuated ERK activation. However, upregulation of
MDM2, which is activated at the time of PDGF-independ-
ent PDGFR activation, was almost completely blocked by
PDGFRα deletion in hepatocytes when WT mice liver
showed upregulation of MDM2 after TAA treatment.
Fig. 7 Levels of PDGF-BB and -CC in Hep3B and LX2 co-culture medium. *P < 0.05, compared to LX2 cells co-cultured with PDGFRα-preserved
Hep3B cells
Fig. 8 Assessment of PDGFRα expression in the human liver with hepatitis without liver fibrosis. a Immunohistochemistry of liver specimens with
hepatitis showed the presence of PDGFRα at the hepatocyte membrane (arrows) and in nonparenchymal cells (arrowheads), whereas normal-liver
specimens showed no PDGFRα staining. Original magnification, × 400. b Whole-cell lysates from pathologically proven hepatitis tissue without
significant fibrosis (n = 7) were examined for col1α(I) and PDGFRα mRNA levels compared to those in normal liver tissue (n = 7)
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Although both hepatocytes and HSCs from TAA-treated
livers had elevated MDM2 expression, the upregulation in
hepatocytes was about one thousand-fold higher than that
in HSCs. Therefore, PDGFRα in hepatocytes might be
predominantly activated by non-PDGF mediated mecha-
nisms; this warrants further research.
Elevated levels of TGFβ are seen in liver fibrosis and
TGFβ overexpression results in liver fibrosis [48, 49].
TGFβ binds to cell surface receptors to initiate intracellu-
lar signal transduction pathways, including activation of
Smad proteins [50–52]. Smad2 and Smad3 form com-
plexes with Smad4 to activate gene expression. Smad7, an
inhibitory Smad, disrupts receptor activation of Smad2/3,
which inhibits TGFβ signaling in a negative feedback
loop [53–55]. Activation of PDGFRα ligands by excess
PDGF-C upregulates TGFβ/Smad3 signaling to facili-
tate liver fibrosis and blocking of Smad3 signaling at-
tenuates PDGF-C–induced liver fibrosis [38]. Deletion
of PDGFRα in hepatocytes results in upregulation of
TGFβ and Smad2/3 expression in the whole liver. How-
ever, this increase in TGFβ and Smad2/3 expression is
offset by overexpression of Smad7, resulting in attenu-
ation of TAA-induced liver fibrosis. The cellular source
of elevated TGFβ, Smad2/3, and Smad7 in the liver
after hepatocyte PDGFRα deletion is unclear. However,
co-culture of PDGFRα-deleted hepatocytes and normal
HSCs resulted in significant upregulation of TGFβ and
Smad2/3 expression in HSCs and maintenance of Smad7
expression.
Particles of injured hepatocytes, as apoptotic bodies,
promote secretion of proinflammatory and fibrogenic cy-
tokines from neighboring inflammatory cells such as mac-
rophages [56]. In addition, damage-associated molecular
patterns (DAMPs) have been suggested to be released
from injured hepatocytes; this may induce liver fibrosis
[57]. It can be speculated that PDGFRα in injured hepato-
cytes induces liver fibrosis by promoting the release of
DAMPs and activating HSCs. Although PDGRα-deleted
HCC cells exhibit enhanced apoptosis [43], this was not
so for non-cancerous hepatocytes in this study.
Conclusions
Our findings suggest that although PDGFRα expression
in normal hepatocytes is negligible, it is upregulated by
liver insult and plays a vital role in liver fibrosis by facili-
tating the activation and proliferation of HSCs.
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